Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.30 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24915007 | 0.77 | BCHE (0.42) | HTR2CSLC6A4KDM4EALDH1A1 | |
| SCHEMBL13104411 | 0.76 | SMYD3 (0.41) | ALDH1A1PSMB8PSMB9 | |
| SCHEMBL17844766 | 0.76 | KDM4E (0.35) | HTR2CSLC6A4KDM4EALDH1A1 | |
| SCHEMBL24915150 | 0.76 | HTR2C (0.38) | HTR2CSLC6A4KDM4EALDH1A1 | |
| SCHEMBL26970990 | 0.75 | PSMB8 (0.33) | PSMB8PSMB9 | |
| SCHEMBL15273645 | 0.75 | PSMB8 (0.35) | PSMB8PSMB9 | |
| SCHEMBL24915555 | 0.73 | HTR2C (0.39) | HTR2CSLC6A4KDM4EALDH1A1 | |
| SCHEMBL24914928 | 0.72 | KDM4E (0.33) | HTR2CSLC6A4KDM4EALDH1A1 | |
| SCHEMBL26140221 | 0.71 | KDM4E (0.32) | HTR2CSLC6A4KDM4EALDH1A1 | |
| SCHEMBL24914927 | 0.71 | KDM4E (0.32) | HTR2CSLC6A4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4122927-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2023-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | ADORA2A, ADORA2B, ADORA3 | HTR2C 58/4885SLC6A4 380/4885KDM4E 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.